These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 27553774)

  • 1. Emerging role of chemokine CC motif ligand 4 related mechanisms in diabetes mellitus and cardiovascular disease: friends or foes?
    Chang TT; Chen JW
    Cardiovasc Diabetol; 2016 Aug; 15(1):117. PubMed ID: 27553774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Resolution of Diabetes: C-C Chemokine Motif Ligand 4 Is a Common Target in Different Types of Diabetes by Protecting Pancreatic Islet Cell and Modulating Inflammation.
    Chang TT; Lin LY; Chen JW
    Front Immunol; 2021; 12():650626. PubMed ID: 33968046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CCL4 Signaling in the Tumor Microenvironment.
    Mukaida N; Sasaki SI; Baba T
    Adv Exp Med Biol; 2020; 1231():23-32. PubMed ID: 32060843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysregulated CC receptor/ligand in monocytes/macrophages from tongue squamous cell carcinoma patients is partially rectified by interferon α-2b.
    Chakraborty K; Bose A; Goswami KK; Mukherjee KK; Goswami S; Ghosh D; Chakraborty T; Sarkar K; Pal S; Bhowmick A; Biswas J; Baral R
    Hum Immunol; 2012 Jan; 73(1):38-47. PubMed ID: 22085486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FGF21: a novel prospect for the treatment of metabolic diseases.
    Kharitonenkov A; Shanafelt AB
    Curr Opin Investig Drugs; 2009 Apr; 10(4):359-64. PubMed ID: 19337957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXC chemokine ligand 4 (CXCL4) down-regulates CC chemokine receptor expression on human monocytes.
    Schwartzkopff F; Petersen F; Grimm TA; Brandt E
    Innate Immun; 2012 Feb; 18(1):124-39. PubMed ID: 21088050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of C-C motif chemokine ligand 4 in the porcine endometrium during the presence of the maternal-fetal interface.
    Lim W; Bae H; Bazer FW; Song G
    Dev Biol; 2018 Sep; 441(1):146-158. PubMed ID: 30056935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. I-TAC/CXCL11 is a natural antagonist for CCR5.
    Petkovic V; Moghini C; Paoletti S; Uguccioni M; Gerber B
    J Leukoc Biol; 2004 Sep; 76(3):701-8. PubMed ID: 15178708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging importance of chemokine receptor CXCR3 and its ligands in cardiovascular diseases.
    Altara R; Manca M; Brandão RD; Zeidan A; Booz GW; Zouein FA
    Clin Sci (Lond); 2016 Apr; 130(7):463-78. PubMed ID: 26888559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 27-Hydroxycholesterol and 7alpha-hydroxycholesterol trigger a sequence of events leading to migration of CCR5-expressing Th1 lymphocytes.
    Kim SM; Kim BY; Lee SA; Eo SK; Yun Y; Kim CD; Kim K
    Toxicol Appl Pharmacol; 2014 Feb; 274(3):462-70. PubMed ID: 24370436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virus stimulation of human mast cells results in the recruitment of CD56⁺ T cells by a mechanism dependent on CCR5 ligands.
    McAlpine SM; Issekutz TB; Marshall JS
    FASEB J; 2012 Mar; 26(3):1280-9. PubMed ID: 22125314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphisms of chemokine and chemokine receptor genes in Type 1 diabetes mellitus and its complications.
    Yang B; Houlberg K; Millward A; Demaine A
    Cytokine; 2004 May; 26(3):114-21. PubMed ID: 15135805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppressive effect of insulin infusion on chemokines and chemokine receptors.
    Ghanim H; Korzeniewski K; Sia CL; Abuaysheh S; Lohano T; Chaudhuri A; Dandona P
    Diabetes Care; 2010 May; 33(5):1103-8. PubMed ID: 20200310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged increase in rat hippocampal chemokine signalling after status epilepticus.
    Kan AA; van der Hel WS; Kolk SM; Bos IW; Verlinde SA; van Nieuwenhuizen O; de Graan PN
    J Neuroimmunol; 2012 Apr; 245(1-2):15-22. PubMed ID: 22353418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monocyte Chemoattractant Protein 1 (MCP-1) in obesity and diabetes.
    Panee J
    Cytokine; 2012 Oct; 60(1):1-12. PubMed ID: 22766373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relation of circulating concentrations of chemokine receptor CCR5 ligands to C-peptide, proinsulin and HbA1c and disease progression in type 1 diabetes.
    Pfleger C; Kaas A; Hansen L; Alizadeh B; Hougaard P; Holl R; Kolb H; Roep BO; Mortensen HB; Schloot NC;
    Clin Immunol; 2008 Jul; 128(1):57-65. PubMed ID: 18434252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rubratoxin-B-induced secretion of chemokine ligands of cysteine-cysteine motif chemokine receptor 5 (CCR5) and its dependence on heat shock protein 90 in HL60 cells.
    Nagashima H
    Environ Toxicol Pharmacol; 2015 Nov; 40(3):997-1000. PubMed ID: 26595743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CCR2 and CCR5 chemokine receptors differentially influence the development of autoimmune diabetes in the NOD mouse.
    Solomon M; Balasa B; Sarvetnick N
    Autoimmunity; 2010 Mar; 43(2):156-63. PubMed ID: 19824873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered chemokine levels in individuals at risk of Type 1 diabetes mellitus.
    Hanifi-Moghaddam P; Kappler S; Seissler J; Müller-Scholze S; Martin S; Roep BO; Strassburger K; Kolb H; Schloot NC
    Diabet Med; 2006 Feb; 23(2):156-63. PubMed ID: 16433713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCL7 as a novel inflammatory mediator in cardiovascular disease, diabetes mellitus, and kidney disease.
    Chang TT; Chen C; Chen JW
    Cardiovasc Diabetol; 2022 Sep; 21(1):185. PubMed ID: 36109744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.